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Maternal immune tolerance of the fetus is indispensable for a healthy pregnancy outcome.
Nowhere is this immune tolerance more important than at the fetal–maternal interface – the
decidua, the site of implantation, and placentation. Indeed, many lines of evidence sug-
gest an immunological origin to the common pregnancy-related disorder, pre-eclampsia.
Within the innate immune system, decidual NK cells and antigen presenting cells (includ-
ing dendritic cells and macrophages) make up a large proportion of the decidual leukocyte
population, and are thought to modulate vascular remodeling and trophoblast invasion. On
the other hand, within the adaptive immune system, Foxp3+ regulatory T cells are crucial
for ensuring immune tolerance toward the semi-allogeneic fetus. Additionally, another pop-
ulation of CD4+HLA-G+ suppressor T cells has also been identified as a potential player
in the maintenance of immune tolerance. More recently, studies are beginning to unravel
the potential interactions between the innate and the adaptive immune system within the
decidua, that are required to maintain a healthy pregnancy. In this review, we discuss the
recent advances exploring the complex crosstalk between the innate and the adaptive
immune system during human pregnancy.
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INTRODUCTION
Pregnancy presents a significant challenge to the maternal immune
system. In humans, the maternal immune system must tolerate the
semi-allogeneic fetus throughout the 9 months of pregnancy. The
remarkable nature of this phenomenon was recognized by Peter
Medawar in the 1950s (1), whose work on skin graft rejection in
genetically different individuals, led him to perceive this appar-
ent immunological paradox. At the time, he proposed that three
factors contribute to this phenomenon: (1) the anatomical separa-
tion between the mother and the fetus, (2) the reduced antigenic
property of the fetus, and (3) the immunological inertness of the
maternal immune system.
These proposals have significantly influenced subsequent
research in the field. Indeed, it is now well-known that fetal cells
are largely separated from the maternal immune system, with the
point of contact being fetal extravillous trophoblast (EVT) cells,
which have poor antigenic properties owing to the lack of expres-
sion of classical MHC class I (except HLA-C) and MHC class II
molecules (2). However, as fetal–maternal microchimerism is a
well-recognized occurrence during human pregnancy, fetal cells
frequently induce maternal immune activation (3, 4) as evidenced
by the detection of anti-fetal HLA antibodies in maternal serum
during pregnancy (5, 6). Additionally, although direct MHC pre-
sentation of fetal antigens by fetal cells generally does not occur,
fetal antigens can be processed and presented by maternal anti-
gen presenting cells (APCs) at the fetal–maternal interface (7).
Indeed, various different subsets of maternal immune cells are
present at the fetal–maternal interface, which is the decidua, the
mucous membrane (endometrium) of the pregnant uterus. In fact,
up to 50% of the cells in the decidua are maternal immune cells
(8). The decidua is therefore, an important site where the mater-
nal immune system encounters fetal antigens and must develop
tolerance mechanisms.
Not surprisingly, many of the pregnancy-related disorders such
as recurrent miscarriages and pre-eclampsia are thought to be
due to the breakdown of this immune tolerance (6, 9, 10). In
pre-eclampsia, whilst the clinical manifestations such as hyper-
tension and proteinuria are thought to be due to endotheliopathy
secondary to insufficient placentation (11, 12), the shallow fetal
trophoblast invasion is likely related to partial breakdown of
maternal–fetal immune tolerance (9).
In this review, we will explore the role of decidual innate and
the adaptive immune cells in facilitating tolerance to the fetus. In
particular, we will highlight some of the recent advances docu-
menting the interaction between these cells, drawing comparisons
between healthy human pregnancy and pre-eclampsia.
INNATE IMMUNE CELLS AT THE FETAL–MATERNAL
INTERFACE
DECIDUAL ANTIGEN PRESENTING CELLS DURING PREGNANCY
Antigen presenting cells are likely to be important players in the
mediation of immune tolerance in the decidua. In mice, a previous
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study has shown that maternal APCs take up apoptotic debris
from the fetal/placental cells and present fetal antigens to mater-
nal T cells. As the major histocompatibility antigens (classical
MHC I and II antigens) are suppressed on fetal trophoblast cells
to evade maternal immune recognition, antigen presentation of
fetal minor histocompatibility antigens by maternal APCs is an
important route for immune recognition (7). Therefore, explor-
ing the characteristics of the decidual APCs and their interaction
with decidual T cells is of great importance in the understanding
of fetal–maternal immune tolerance.
DECIDUAL DENDRITIC CELLS IN HEALTHY PREGNANCY
AND PRE-ECLAMPSIA
Study of decidual dendritic cells (dDCs) has been difficult, not
only because isolation of decidual cells including dDCs can be
technically demanding, but also because phenotypic definition of
DCs is controversial as there is no single specific marker for DCs.
In this particular section, we refer primarily to the lineage negative
HLA-DR+ classical DCs. Using lineage negative and HLA-DR+ as
combination marker for dendritic cell (DC), Gardener et al. found
that dDC comprises ~1% of the total decidual cell isolates in first
trimester decidua (13). These DCs were CD11c+, CD1a−, and
CD123−, indicating a myeloid rather than plasmacytoid origin.
Interestingly, they showed that these DCs were DC-SIGN−, com-
pared to CD14+ “macrophages,” which were DC-SIGN+. These
results were further explored in a later study by Ban et al., who
showed that first trimester lineage negative and HLA-DR+ dDCs
predominantly expressed BDCA1 and BDCA3 surface antigens,
corresponding with different subsets of myeloid DCs (14).
Overall, due to the difficulty in decidual mononuclear cell iso-
lation and the rarity of dDCs, functional studies on these DCs are
scarce. In a study by Kammerer et al., the authors demonstrated
a small population of mature CD83+ DCs as well as CD1a+ DCs
in human first trimester decidua, by both immunohistochemistry
and flow cytometry (15). They went on to show that the CD83+
cells are potent stimulators in mixed lymphocyte reactions compa-
rable to mature peripheral blood monocyte-derived DCs. Another
study by Laskarin et al. showed that CD1a+ DC isolated from
decidua stimulated NK cell activity and proliferation better than
decidual CD83+ DCs (16). Their experiments were done in vitro,
however, and there was no demonstration of CD1a+ or CD83+DC
interaction with decidual NK cells in situ. An earlier study demon-
strated that lineage− and HLA-DR+ DCs in first trimester human
decidua were mostly of myeloid origin, but produced less IL-12
compared to their peripheral counterparts. They also showed that
dDCs were more likely to prime CD4 cells into a Th2 phenotype
compared to their peripheral counterparts (17). The authors con-
cluded that such polarization of the immune response toward Th2
has potential roles in averting Th1-mediated rejection of the fetus.
Studies of decidual DC functions in mice are more defini-
tive. Selective ablation of CD11c+ decidual DCs leads to failure
of decidualization and embryo implantation (18), highlighting
the potential role of dDCs in the initiation of successful preg-
nancy. Another study demonstrated that during murine preg-
nancy, decidual CD11c+ DCs fail to migrate to draining lymph
nodes due to absent lymphatic vessels and CCL21 (ligand for
lymphoid homing CCR7) expression in the murine decidua
and therefore do not significantly contribute to anti-fetal T cell
responses (19). However, it is important to note that in contrast
to mice, lymphatic vessels are abundant and CCL21 is expressed
within the human decidua (20, 21), which therefore might facili-
tate decidual DC migration in humans. Furthermore, whilst these
studies shed light on the function of CD11c+ DCs in mice, it is
difficult to know whether these CD11c+ cells are comparable to
the lineage negative, HLA-DR+CD11c+ DCs in human decidua.
Nevertheless, at least in mice, decidual CD11c+ DCs appear to
be important for the initiation of pregnancy and maintenance of
immune tolerance.
So far, few studies have examined the role of decidual DCs
in pre-eclampsia. Huang et al. found that there were increased
numbers of CD83+ and DC-SIGN+ APCs in the pre-eclamptic
decidua (22). Scholz et al. partially confirmed this finding showing
increased numbers of DC-SIGN+ cells in the decidua of patients
affected by HELLP syndrome, a severe form of pre-eclampsia (23).
However, it is important to note that DC-SIGN+ APCs in particu-
lar, are likely a different group of cells distinct from lineage negative
HLA-DR+CD11c+ classical myeloid DCs (discussed above), as
highlighted in subsequent sections.
DECIDUAL MACROPHAGES IN HEALTHY PREGNANCY AND
PRE-ECLAMPSIA
Macrophages are specialized phagocytic cells of the innate immune
system and they are present in every organ of the body in one
form or another. Macrophages, like DCs, are part of the mononu-
clear phagocyte system consisting of committed bone marrow
precursors, peripheral blood monocytes and DCs, as well as tissue
macrophages and DCs (24). Whilst many have attempted to sep-
arate macrophages from DCs based on phenotype and function,
significant controversy exists as to whether these cells are indeed
distinct from one another (25).
CD14+ decidual macrophages (dMacs) comprise about 10–
20% of decidual CD45+ leukocyte population (26). Their phe-
notype has been characterized in several studies. In a study of
human CD14+ dMacs, Heikinnen et al. (27) observed that com-
pared to the peripheral blood monocytes, dMacs expressed lower
level of co-stimulatory molecule CD86. This coupled with the
expression of indoleamine 2,3-dioxygenase (IDO), known to have
an immunosuppressive effect on T cells, led them to conclude
that dMacs have an “immunosuppressive” phenotype. Notably
however, their data showed that dMacs expressed higher level
of HLA-DR, as well as the co-stimulatory molecule CD80, com-
pared to peripheral blood monocytes. Another study by Repnik
et al. (28) confirmed the expression of HLA-DR, CD80, and CD86
on dMacs. They further showed that expression of these markers
were higher earlier in the gestation, implying greater dMac activa-
tion at the time of implantation. A more recent study examined
dMac in the first trimester using gene micro-array analysis. The
authors found that compared to peripheral blood macrophages,
dMacs have a gene expression profile, which biases toward alter-
natively activated macrophages or M2 phenotype, which suggests
that dMacs are likely immunosuppressive (29).
In a study of dMac function, Mizuno et al. (30) showed that
dMacs have antigen presentation capacity, but are less stimula-
tory and produce less IL-1 than peripheral blood monocytes in
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mixed lymphocyte reactions. The suppressive activity of dMac
has also been supported by other studies (31). The cytokine pro-
file of dMac was also examined by Heikkinen et al., showing
that term decidual CD14+ dMac spontaneously produced sig-
nificantly more IL-10 than peripheral blood monocytes ex vivo.
In addition, these macrophages were less able to differentiate into
mature DCs in vitro under polarizing conditions, possibly owing
to their production of IL-10 (27). Thus, it is likely that dMacs
are a special subset of APCs specialized in tolerance induction.
In addition, there is evidence that dMacs are also involved in
vascular remodeling (5, 32) and parturition in the peripartum
period (33, 34).
In a large study with 33 pre-eclamptic patients and 66 con-
trols, Rieger et al. examined decidual leukocyte populations using
flow cytometry (35). They did not find any difference in HLA-DR,
dendritic cell specific intercellular adhesion molecule 3 (ICAM3)
grabbing non-integrin (DC-SIGN), or CD14 expression within
CD45+ cells between healthy pregnancy and pre-eclampsia. In
a smaller study, Schonkeren et al. compared the distribution and
phenotype of CD14+ dMacs between preterm control pregnancies
and preterm pre-eclampsia (36). Using sequential or two-color
immunohistochemistry, they found reduced CD163/CD14 ratio
[CD163 being a marker of alternatively activated macrophage
or M2 (37)], increased DC-SIGN/CD14 ratio, and reduced IL-
10 expression in preterm pre-eclamptic pregnancies, which may
suggest a more pro-inflammatory phenotype of dMacs in pre-
eclampsia. More recently, we examined decidual CD14+ APCs in
more detail during healthy pregnancy and pre-eclampsia using
multi-color flow cytometry (38). However, in this study, we
focused on the distinct subset of CD14+DC-SIGN+ APCs, which
is discussed below.
DECIDUAL CD14+DC-SIGN+ APCs IN HEALTHY PREGNANCY AND
PRE-ECLAMPSIA
Dendritic cell specific ICAM3 grabbing non-integrin is an ICAM3
receptor, where ICAM3 is an adhesion molecule. DC-SIGN, also
known as CD209, is important for the initiation of DC and T cell
interaction (39). Despite its name, DC-SIGN may be expressed
by a variety of APCs other than classical lineage negative HLA-
DR+ DCs, including CD14+ macrophages (40). Nevertheless, in
monocyte-derived DCs, DC-SIGN is one of the markers upregu-
lated in maturing DCs in mice (33) and humans (39). Therefore,
whilst the expression of DC-SIGN is not DC specific, it probably
marks myeloid cells, which are on the DC differentiation pathway
(i.e., immature DCs).
In the human decidua, Kammerer et al. found that a significant
percentage of CD14+HLA-DR+ APCs expressed DC-SIGN in the
first trimester decidua (41). These CD14+DC-SIGN+ cells did
not express CD83, but expressed CD4. Interestingly, the authors
found these cells to be unique to the decidua in pregnancy and
not in normal non-pregnant endometrium. In addition, these
cells show a high proliferative rate and good antigen uptake,
but poor stimulatory activity in MLR. Importantly, these cells
have a veiled appearance typical of immature DCs on immuno-
histochemistry and can be matured in vitro with a cocktail of
inflammatory cytokines into CD83+ mature DCs, with decreased
CD14 and DC-SIGN expression, as well as potent stimulatory
activity in MLR. The authors concluded that these CD14+DC-
SIGN+ cells are likely to be precursors of DCs and may play an
important role in mediating fetal–maternal immune tolerance.
Repnik et al. also confirmed DC-SIGN expression in decidual
CD14+ APCs and showed that DC-SIGN expression peaked in
the second trimester (28). Obviously, decidual CD14+DC-SIGN+
APCs would be included in studies examining dMacs in view
of their CD14 expression. Such studies include recent work by
Svensson et al., who showed that CD14+ dMacs can be divided
into two distinct groups based on ICAM3 expression, with the
ICAM3− group expressing DC-SIGN and markers of alternative
(M2) macrophage activation (CD163, CD206, neuropilin) (42).
They further showed that the phenotype of these DC-SIGN+
dMacs may be replicated in vitro (with similar gene expression
profile) in the presence of M-CSF (and/or GM-CSF) plus IL-10.
Another study divided first trimester CD14+ dMacs into CD11chi
and CD11clo cells corresponding to DC-SIGN− and DC-SIGN+
cells, respectively (43). Using gene expression profiles, the authors
here showed that neither of the CD11chi or CD11clo macrophages
corresponds to in vitro differentiated M1 or M2 macrophages
exactly, though CD11chi macrophages were skewed toward mater-
nal peripheral blood monocytes and shared common genes with
synovial macrophages from rheumatoid arthritis patients. In the
same study, the authors showed that CD11chi dMac produced sig-
nificantly more TNFα, IL-6, and paradoxically IL-10 compared to
CD11clo macrophages. On the other hand, there was a slight trend
toward increased TGFβ secretion by CD11clo cells.
Collectively, these studies confirm that the human decidua
harbors two distinct populations of CD14+ APCs, one which
is CD11cloDC-SIGN+CD206+CD163+neuropilin+ICAM3− and
is likely immunoregulatory and important for tolerance induc-
tion, the other which is CD11chiDC-SIGN−CD206−CD163−
neuropilin− ICAM3+ and probably pro-inflammatory and
important for tissue remodeling. In our recent study, we examined
term decidual CD14+DC-SIGN+APCs in detail using multi-color
flow cytometry. We show that decidual CD14+DC-SIGN+ APCs
expressed significantly higher amount of tolerogenic molecules
(HLA-G and ILT4), lymphoid homing molecule (CCR7), as well as
antigen presentation apparatus (HLA-DR, CD80, CD86), but less
CD14 than CD14+DC-SIGN− cells (38). This suggests that decid-
ual CD14+DC-SIGN+ APCs may be further along the differenti-
ation pathway than their DC-SIGN− counterparts and that these
cells possess enhanced tolerogenic properties. Both of these obser-
vations are consistent with the previously described studies (42,
43). The tolerogenic properties are likely induced by IL-10, which
is known to upregulate HLA-G and ILT4 (44, 45). Interestingly
in vitro, we were able to differentiate peripheral blood monocytes
into CD14+DC-SIGN+HLA-G+ILT4+ APCs by adding IL-10 to
the DC polarizing protocol (with GM-CSF and IL-4) (46). In the
context of the blurred border between macrophages and DCs, and
given that the phenotype of decidual DC-SIGN+ APCs may be
replicated in vitro with both DC or macrophage polarizing proto-
cols, we suggest that decidual CD14+DC-SIGN+ APCs are likely
an intermediate cell type on the continuum of macrophage/DC
differentiation under the influence of IL-10. Whether decidual
CD14+DC-SIGN− APCs are completely distinct from, or on the
same developmental continuum as, CD14+DC-SIGN+ APCs is
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Table 1 | Differences between decidual DC-SIGN+ and DC-SIGN− APCs.
DC-SIGN+ DC-SIGN−
LINEAGE MARKER
CD14 (38) Intermediate High






CD11c (43) Low High
ICAM3 (42) Low High








TNFα, IL-6 Low High
IL-10 Low High
TGFβ High Intermediate
% CD14+ cells (first
trimester) (43)
~70% 20–30%






Likely function Immune regulation Tissue
remodeling
currently unknown. However, the later hypothesis is supported
by the fact that CD14+DC-SIGN− APCs are closer to peripheral
blood monocytes (43) and possess less antigen presentation appa-
ratus. The differences between decidual CD14+DC-SIGN+ and
CD14+DC-SIGN− APCs are summarized in Table 1.
Interestingly in pre-eclampsia, we found an increased percent-
age of DC-SIGN+ APCs within the CD14+ population, however,
pre-eclamptic decidual CD14+DC-SIGN+ APCs expressed signif-
icantly less HLA-G and ILT4 compared to the same cells in healthy
pregnancy, suggestive of reduced tolerogenic capacity. We specu-
late that this phenotypic difference may be related to the reduced
placental IL-10 levels in pre-eclamptic pregnancies (47).
In summary, there are several different types of APCs present
in the decidua, including lineage negative HLA-DR+CD11c+ clas-
sical DCs, mature CD83+ DCs, CD1a+ DCs, and CD14+DC-
SIGN− dMac, which may have developed from peripheral blood
monocytes and are probably precursors to decidual CD14+DC-
SIGN+ APCs. Their potential relationships and differences
in healthy pregnancy and pre-eclampsia are summarized in
Figure 1.
DECIDUAL NK CELLS IN HEALTHY PREGNANCY AND PRE-ECLAMPSIA
Decidual NK cells (dNK) are the most abundant maternal leuko-
cytes in the decidua, especially in the first trimester, making up
70% of the maternal CD45+ leukocyte population. (48) The dNK
cells are distinct from majority of peripheral blood NK cells, in
that they are large, granular, and are CD56hi and CD16− (8). The
origin of these cells is unclear, although some have proposed pos-
sible recruitment of a subset of peripheral blood CD56hi NK cells
into the decidua (49). Interestingly, during early pregnancy, dNK
accumulate as a dense infiltrate around the trophoblast cells, but
they progressively decrease in number from mid-gestation onward
(50). This timing seems to implicate that dNK cells may be involved
in modulating trophoblast invasion and vascular remodeling.
Indeed, dNK have been shown to produce vascular endothelial
growth factor C (VEGFC), placental growth factor (PIGF), and
angiopoietin 2 (ANG2).
Decidual NK cells may also be important in modulating the
degree of trophoblast invasion, as they are seen in close proxim-
ity to the invading trophoblasts in the decidua. Certainly, dNK
have been shown to express killer inhibitory receptor (KIR) (51),
CD94/NKG2A (52), and ILT2 (53), which recognize HLA-C and
HLA-G, respectively, expressed on trophoblast cells. The HLA-C–
KIR interaction is thought to be important in the pathogenesis
of pre-eclampsia. As HLA-C is dimorphic and KIR polymor-
phic, it has been shown that certain combinations of maternal
KIR and fetal HLA-C lead to an increased risk of pre-eclampsia,
possibly through modulation of trophoblast migration, imply-
ing that HLA-C–KIR interaction is important in placentation (54,
55). However, NK cell KIR and HLA-C mismatch clearly does not
explain all cases of pre-eclampsia, since only 30% of pre-eclamptic
pregnancies have the at-risk maternal KIR phenotype (KIR AA)
(54). HLA-G–ILT2 interaction on NK cells on the other hand,
has been shown to increase dNK secretion of inflammatory and
proangiogenic factors such as IL-1β, IL-6, TNF, and IL-8 (56). NK
cells themselves are also susceptible to modulation by the decidual
cytokine milieu. Indeed, dNK cells are thought to be the mediator
of fetal demise in IL-10-deficient mice treated with LPS, which
conversely can be rescued by administration of IL-10 (57). This
suggests that IL-10 may modulate dNK cell cytotoxicity.
Collectively, these data suggest that dNK cells are important for
modulation of trophoblast invasion and decidual vascularization
in pregnancy. However, the recognition and tolerance of pater-
nal allo-antigens via APC presentation during pregnancy, clearly
requires the participation of other limbs of the immune system,
such as the adaptive immune cells.
ADAPTIVE IMMUNE CELLS AT THE FETAL–MATERNAL
INTERFACE
The adaptive immune system distinguishes itself from the innate
immune system by its antigen specificity and immunological
memory. Therefore, the fact that pre-eclampsia is essentially a
disease of primigravida and subsequent pregnancies with the
same partner protect against pre-eclampsia (58, 59), supports
the involvement of the adaptive immune system. Within the
lymphocyte subsets, CD4+Foxp3+ regulatory T (Treg) cells in
particular have been the subject of many studies, with their piv-
otal role in pregnancy now firmly established. Th17 cells, the
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FIGURE 1 |Various APCs in the human decidua. Whether decidual
CD14+DC-SIGN− dMacs and CD14+DC-SIGN+ APCs are derived
independently from peripheral blood (PB) monocytes is unknown.
Alternatively, CD14+DC-SIGN− dMacs may be on a continuum of DC
differentiation, where local IL-10, M-CSF, and GM-CSF drive their
development into CD14+DC-SIGN+ APCs expressing HLA-G and ILT4.
These APCs may be matured into CD83+ mature DCs (mDCs) under the
influence of inflammatory cytokines, which in healthy pregnancy is
minimal. In pre-eclampsia, both CD14+DC-SIGN+ APCs and mDCs
increase, probably driven by increased inflammatory cytokines in this
disease. This is coupled with reduced HLA-G and ILT4 expression by
CD14+DC-SIGN+ APCs, likely due to reduced local IL-10 levels. Whilst
CD11c+HLA-DR+ and CD1a+ DCs have been identified in human decidua,
their roles and relationship with CD83+ DCs are unclear.
pro-inflammatory antagonist of Treg cells have also become a focus
of studies in the last few years. More recently, CD4+HLA-G+ sup-
pressor T cells have also been implicated for their potential role
in healthy pregnancy and pre-eclampsia. Whilst other cells within
the adaptive immune system such as Th1, Th2, gamma-delta T
cells, and CD8+ T cells also play a role in fetal–maternal immune
tolerance (60–63), our focus in this review will be on Treg, Th17,
and CD4+HLA-G+ suppressor T cells.
Treg CELLS IN HEALTHY PREGNANCY AND PRE-ECLAMPSIA
Foxp3+ Treg cells are a unique subset of suppressive CD4+ T
helper cells indispensable for immune tolerance to self- and
foreign-antigens in humans and mice (64–67). Several authors
have shown that in pregnancy, there is an expansion of peripheral
blood Treg cell pool in both humans (68, 69) and mice (70). The
study by Somerset et al. showed that Treg cell population seems
to peak in the second trimester and thereafter decreases to slightly
above normal levels at delivery of the conceptus. Some have sug-
gested that this expansion of Treg cell is not allo-antigen driven at
least in the mice, as both syngeneically and allogeneically pregnant
mice show expansion of the Treg cell population (70). However, the
authors did not show a direct comparison of Treg cell percentage
between syngeneic and allogeneic pregnancies. In contrast, Zhao
et al. showed through direct comparison, that the percentage of
peripheral blood Treg cells in allogeneic pregnancy is higher com-
pared to syngeneic pregnancy, suggesting that the expansion of
Treg cell is at least partially allo-antigen driven (71). Since then,
other studies have demonstrated the fetal antigen-specific nature
of maternal Treg cells during pregnancy (72, 73), further support-
ing the role of fetal allo-antigen in Treg cell expansion. Therefore,
whilst other factors such as pregnancy-related hormones can also
contribute to Treg cell expansion (74–76), it is likely that fetal
allo-antigen stimulation is the primary driving force.
Given the decidua is the fetal–maternal interface and the likely
place of fetal antigen encounter, it is not surprising that the
proportion of Treg cells is even greater in the decidua during preg-
nancy compared to the peripheral blood (77, 78). The question is
whether these Treg cells are recruited from the peripheral blood
or induced locally. Currently in humans, despite some contro-
versy, the only marker that differentiates thymus-derived natural
Treg (nTreg) cells from peripherally induced Treg (iTreg) is Helios,
where Helios+ Treg cells are nTreg cells, which have acquired Treg
cell phenotype in the thymus, whereas Helios− Treg cells have dif-
ferentiated in the peripheral tissues/lymph nodes from naïve T
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cells (79). Based on this premise, we found that the proportion of
Helios− iTreg cells was significantly higher in the decidua com-
pared to the peripheral blood (38). Interestingly, our results also
indicate that the previously described peripheral blood expansion
of Treg cells associated with healthy pregnancy is accounted for
by the expansion of iTreg cells, and not nTreg cells. This sug-
gests that in healthy pregnancy, iTreg cells are induced locally in
the decidua/draining lymph nodes most likely in response to fetal
allo-antigens. This observation is consistent with the murine stud-
ies previously discussed (72, 73), as well as the fact that iTreg cells
are thought to facilitate tolerance to foreign- (in this case fetal)
and self-antigens, whereas nTreg cells are primarily involved in
self-tolerance (67, 80, 81).
Functionally, in vivo experiments in the murine model have
shown that Treg cells are important for fetal–maternal immune
tolerance. Aluvihare et al. showed that adoptive transfer of whole
T cell populations to T cell-deficient pregnant mice did not result
in fetal rejection, whereas transfer of T cells depleted of CD25+
Treg cells led to fetal demise, especially in allogeneic pregnancies
(70). This was confirmed by another method, where PC61 mono-
clonal antibody against CD25 was used to deplete Tregs in murine
syngeneic and allogeneic pregnancy. The authors found that fewer
fetuses in allogeneic pregnancies survived to term whereas syn-
geneic pregnancies were not affected by Treg cell depletion (82).
This indicates that Treg cells are critically required for allogeneic
but not syngeneic pregnancy.
Whereas total Treg cell depletion leads to almost complete fetal
rejection (70, 82), depletion of the iTreg, but not nTreg, compart-
ment in CNS1 (conserved non-coding sequence 1) deficient mice
(CNS1 being critical for iTreg development) leads to partial fetal
resorption (~10%) and abnormal spiral artery formation in allo-
geneic murine pregnancies (83). This phenotype is reminiscent
of the human disease – pre-eclampsia, where IUGR (intrauter-
ine growth retardation) and abnormal spiral artery remodeling
with shallow placentation is a key pathological feature (84), being
mindful of the caveat that there are significant differences between
human and murine pregnancies (85).
Nevertheless, our investigations did show that the blunted
peripheral blood Treg cell expansion in pre-eclampsia (69, 86, 87)
is primarily due to the failure of iTreg cell expansion,whereas nTreg
cells are not affected. Interestingly in the pre-eclamptic decidua,
whilst we did not find a reduction in total Treg cell percentage,
there was a significant reduction in the percentage of Helios−
iTreg cells compared to healthy pregnancy (38). These observa-
tions suggest that in pre-eclampsia, there is impaired expansion of
iTreg cells in the decidua, with compensatory nTreg cell recruit-
ment to avert fetal rejection. Collectively, these data from murine
and human studies suggest that iTreg and nTreg cells collaborate
to maintain fetal–maternal immune tolerance, such that complete
lack of Treg cells leads to fetal rejection, whereas specific iTreg cell
deficiency results in poor placentation and fetal growth restriction.
Th17 CELLS IN HEALTHY PREGNANCY AND PRE-ECLAMPSIA
Th17 cells are a subset of CD4+ T helper cells, which secrete the
pro-inflammatory cytokines IL-17, IL-22, regulated by the tran-
scription factor RORγt (88). Importantly, both iTreg and Th17
cells are derived from naïve CD4+ T cells under the influence of
TGFβ (89) in a concentration-dependent manner, with high lev-
els of TGFβ favoring iTreg cell induction and low concentrations
favoring development of Th17 cells (88, 90). Additionally, the pres-
ence of the pro-inflammatory cytokine, IL-6 is crucial for skewing
T cell differentiation toward Th17 phenotype (91).
We have previously shown that the percentage of peripheral
blood Th17 cells decreases in healthy pregnancy, in stark contrast
to the expanding iTreg cell population. Whereas in pre-eclampsia,
the percentages of peripheral blood Th17 and iTreg cell subsets
remain comparable to the non-pregnant state. This leads to an
increased Treg: Th17 ratio in healthy pregnancy, which is blunted
in pre-eclampsia (69). These results were later replicated in other
studies (92, 93). Collectively, these observations are congruous
with the raised serum IL-6 level in pre-eclampsia compared to
healthy pregnancy (94), which may contribute to the increased
Th17 cells compared to normal pregnancy. Additionally soluble
endoglin, a circulating TGFβ glycoprotein receptor capable of
inhibiting TGFβ signaling, is elevated in pre-eclampsia (95). This
would likely reduce the degree of TGFβ signaling, hence favor-
ing Th17 cell differentiation. Therefore, current evidence indicates
that in healthy pregnancy, there is a preferential differentiation of
iTreg cell over Th17 cells, which is deranged in pre-eclampsia,
possibly related to altered systemic levels of various factors such as
IL-6 and soluble endoglin (Figure 2).
Currently, few studies have examined Th17 cells in the human
decidua. A study by Mjosberg et al. attempted to examine the
proportions of Th1, Th2, Treg, and Th17 cells in early pregnancy
decidua, however, in this study, the authors used chemokine recep-
tors as surrogate markers for Th1, 2, and 17 cells, which is less than
ideal, they concluded that there is near absence of Th17 cells in
early healthy pregnancy decidua (96). Wang et al. found increased
peripheral blood and decidual Th17 cell percentage in women
with unexplained recurrent miscarriages compared to healthy
pregnancy. In their samples, the percentage of Th17 cells in the
decidua appears to be comparable or even slightly lower than in
FIGURE 2 | Reciprocal development of iTreg andTh17 cells in healthy
pregnancy and pre-eclampsia. In the relative absence of IL-6 and
endoglin, TGFβ signaling enhances iTreg, but not Th17 cell differentiation in
healthy pregnancy. In pre-eclampsia, the elevated level of endoglin could
reduce TGFβ signaling, which in combination with the increased IL-6 level,
would deter iTreg cell induction, but drive Th17 differentiation.
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peripheral blood in both study groups (97). This is in contrast to
another study, which showed higher percentages of Th17 cells in
the decidua in healthy pregnancy (98). Therefore, current evidence
demonstrates that Th17 cells are present in the decidua, although
their prevalence is controversial. Furthermore, no study to date
has examined the presence and prevalence of decidual Th17 cells
in pre-eclampsia. It would be interesting to see whether there is an
increase in decidual Th17 cells in pre-eclampsia, which would add
to the body of evidence implicating local immune dysregulation
in this disease.
CD4+HLA-G+ T CELLS IN HEALTHY PREGNANCY AND PRE-ECLAMPSIA
HLA-G is an atypical MHC class I molecule first discovered on
human trophoblasts (99, 100). It exerts immunosuppressive effects
on various immune cells, including APCs, NK cells, and T cells
(101–103). Therefore, it is not surprising that it is expressed at
immune privileged sites such as the decidua (99), the cornea
(104), and thymic medulla (105). Interestingly, distinct subsets
of HLA-G+ T cells (both CD4+ and CD8+) are present at low
levels in the peripheral blood of healthy donors (106). These cells
are immunosuppressive but do not express Foxp3. They medi-
ate suppression in a HLA-G and IL-10-dependent manner (107).
Some evidence suggests that these cells originate from the thymus
(106), however others have also shown that activated T cells can
also “acquire” HLA-G from HLA-G expressing APCs, through the
process of trogocytosis (108). Trogocytosis is a process by which
membrane fragments including surface molecules are transferred
from one cell to another in a contact-dependent manner (109).
These HLA-G expressing T cells are similarly immunosuppressive
(108, 110).
We and others have shown that the percentage of periph-
eral blood CD4+HLA-G+ T cells is significantly increased in
healthy pregnancy, which is even more pronounced within the
decidua, where up to 20% of the CD4+ T cells are HLA-G+ (46,
111). These CD4+HLA-G+ T cells are more mature and acti-
vated than their HLA-G− counterparts, they are Foxp3− but are
immunosuppressive (46). Importantly, in pre-eclampsia there is
impaired expansion of these CD4+HLA-G+ T cells in both the
peripheral blood and the decidua. This is in keeping with the
reduced serum HLA-G and placental HLA-G level in this dis-
ease, and reinforces the dysregulated adaptive immune responses
in pre-eclampsia.
INNATE AND ADAPTIVE INTERACTION AT THE
FETAL–MATERNAL INTERFACE
The evidence and discussions presented so far have focused
on individual cell populations and their role in fetal–maternal
immune tolerance, however, the immune system clearly does not
work in isolation, but rather like an intricate, changing network.
It is therefore important to investigate the interactions between
the various immune cells, whether innate or adaptive at the fetal–
maternal interface. In the following sections of this review, we
will focus on the current available evidence in this regard and
attempt to present a unifying concept, as well as future research
directions for innate and adaptive immune interactions within the
decidua.
DECIDUAL NK CELL CROSSTALK WITH INNATE AND ADAPTIVE
IMMUNE CELLS
As discussed previously, dNK cells are important for modulat-
ing fetal trophoblast invasion and vascular remodeling. How-
ever, emerging evidence also suggests that dNK cells interact
and modulate other maternal immune cells. Kammerer et al.
first noted that dNK cells are closely associated with decidual
DC-SIGN+ APCs. They further demonstrated that this interac-
tion occurs through ICAM3 (expressed on NK cells) and DC-
SIGN interaction, although it was unclear what this interaction
involves (41).
A later study demonstrated that dNK cells modulate decidual
CD14+ macrophages (dMac) to expand Treg cells in vitro (112).
In this study, Vacca et al. demonstrated that interaction between
dMac and dNK cells led to release of IFNγ by dNK cells, the IFNγ
in turn induces upregulation of IDO in dMac. Importantly, IDO is
known to contribute to immune suppression at the fetal–maternal
interface (113, 114). It works by catabolizing tryptophan into l-
kynurenine, which results in impaired T cell activation and favors
Treg cell induction (115). Indeed, Vacca et al. showed that the IDO
induction was important for subsequent Treg cell expansion by
dMacs cultured with dNK, along with other factors such as TGFβ
and CTLA-4 engagement. Notably, CTLA-4 engagement of APC
co-stimulatory B7 molecules has also been shown to upregulate
IDO expression in APCs (116). This could provide a continuous
positive reinforcement loop, where the expanded CTLA-4 express-
ing Treg cells further enhance APC IDO expression. Interestingly,
l-kynurenine inhibited the ability of peripheral blood NK cells,but
not dNK cells to secrete IFNγ, which may explain how this nega-
tive feedback prevents peripheral blood NK cells from modulating
dMacs in the same way. Although the authors did not clarify, these
“dMacs” are probably decidual DC-SIGN+ APCs, which interact
with ICAM3+ dNK cells via DC-SIGN. It is also important to
note that the authors did not clearly demonstrate de novo Treg
cell induction under these conditions, since the starting periph-
eral blood CD3+ population would contain nTreg cell population.
Nevertheless, the interaction between dNK and dMac appears to
favor Treg cell proliferation and expansion through IFNγ-induced
upregulation of IDO.
Interestingly, a more recent study showed that dNK produc-
tion of IFNγ may be important for averting Th17 differentiation
at the fetal–maternal interface (55). Here, the authors found that
CD56hiCD27+ dNK cells are particularly primed to secrete IFNγ,
which has been shown to inhibit Th17 differentiation via STAT1
activation (117). They went on to show that in the murine model,
deletion of NK cells led to increased Th17 cell accumulation in the
decidua and increased fetal loss. In vitro, dNK cell-derived IFNγ
significantly inhibited Th17 cell differentiation, an effect that was
reversed by IFNγ neutralizing antibodies. Finally they showed that
there is reduced CD56hiCD27+ dNK cell:Th17 cell ratio in the
decidua of women with recurrent miscarriages, accompanied by
reduced IFNγ secretion by dNK cells in these women. These results
suggest that a special subset of CD56hiCD27+ dNK cells may
be important for limiting Th17 cell differentiation and inflam-
mation in normal pregnancy via IFNγ. It is intriguing to con-
template whether this inhibition of Th17 cell differentiation may
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paradoxically promote iTreg cell development, since both develop
along the same pathway and reciprocally inhibit one another (84,
118). Furthermore, whether similar, but perhaps milder, patho-
physiology may be found in pre-eclampsia is also of interest and
requires further investigations.
Thus, these recent results highlight that NK cells are able to
influence both decidual APCs and T cells through their secretion
of IFNγ to promote immune tolerance.
APC AND T CELL INTERACTION AT THE FETAL–MATERNAL INTERFACE
Antigen presenting cells play important roles in shaping T cell
responses and differentiation; T cells in turn also modulate APC
function. In our recent study, we showed by immunohistochem-
istry that decidual DC-SIGN+ APCs are closely associated with
Foxp3+ Treg cells (38). In fact the number of DC-SIGN+ APCs
correlated significantly with Foxp3+ Treg cells in healthy preg-
nancy, but interestingly not in pre-eclampsia, suggesting a dysreg-
ulated relationship between these cells in this disease. We went
on to show that decidual CD14+DC-SIGN+ APCs from healthy
pregnant, but not pre-eclamptic women induced iTreg cells sig-
nificantly more efficiently than CD14+DC-SIGN− APCs. This
suggests that there is an intrinsic defect in decidual CD14+DC-
SIGN+ APCs in pre-eclampsia. This is consistent with the reduced
expression of the tolerogenic molecules HLA-G and ILT4 in this
cell subset in pre-eclampsia. These results are also consistent with
Vacca et al.’s study described in the previous section (112), and
reinforce that decidual DC-SIGN+ APCs are an important pop-
ulation of cells in human pregnancy, which likely present fetal
allo-antigens and induce local iTreg cells. Importantly, in contrast
to CD14+DC-SIGN− APCs, decidual CD14+DC-SIGN+ APCs
express CCR7 (38), which suggests that they may also migrate to
uterine draining lymph nodes and induce iTreg cells there.
The unresolved question is how these CD14+DC-SIGN+ APCs
induce iTreg cells. Vacca et al.’s study suggests that TGFβ and
IDO may be required for this process (112). This raises another
intriguing question, as to whether the elevated endoglin levels
in pre-eclampsia may impair TGFβ signaling and impede iTreg
cell induction whilst promoting Th17 differentiation. It is impor-
tant to note however, that our experiments were done in vitro,
removed from the in vivo environment where endoglin may play
a role. Therefore, our data indicates that there may be an intrin-
sic defect in CD14+DC-SIGN+ APCs in pre-eclampsia. Perhaps
in pre-eclampsia, decidual CD14+DC-SIGN+ APCs secrete less
TGFβ, or have reduced IDO expression?
The abundance of immunosuppressive CD4+HLA-G+ T cells
in the decidua raises the question regarding how these cells have
developed. Since HLA-G could be transferred from cell to cell via
trogocytosis (108, 110, 119), we reasoned that these CD4+ T cells
could have acquired HLA-G from any of the HLA-G expressing
cells in the decidua, including fetal EVT and maternal CD14+DC-
SIGN+ APCs. To this end, we showed that in vitro, decidual
CD14+DC-SIGN+ APCs, but not JEG3 cells (an EVT-like cell
line), were able to induce CD4+HLA-G+ T cells from naïve T cells
(46). This is consistent with the fact that T cell trogocytosis is facili-
tated by the formation of immunological synapse with TCR–MHC
engagement (120–122), since EVTs and JEG3 cells do not express
MHC II. We further showed that the acquisition of HLA-G from T
cells occurred via trogocytosis, since PE labeled HLA-G was passed
from the APC to responding T cells. Therefore, we suggest that in
the human decidua, T cells activated by fetal allo-antigens may
be “silenced” by their acquisition of HLA-G, indeed the HLA-G
expressing T cells in the decidua exhibit an activated phenotype
(46). Importantly in pre-eclampsia, there is significant reduction
of CD4+HLA-G+ T cells, which may be secondary to the reduced
HLA-G expression by decidual CD14+DC-SIGN+ APCs in this
disease.
Based on these recent data, it appears that decidual CD14+DC-
SIGN+ APCs are a unique and important population of cells,
which play central roles in regulating local immune responses by
their interactions with dNK cells and resident CD4+ T cells. As
described previously, decidual CD14+DC-SIGN+ APCs may have
developed under the influence of local IL-10 (42, 46), which is
probably derived from dNK and CD14+DC-SIGN− dMac (41).
Therefore, IL-10 may be a central cytokine driving the differen-
tiation of decidual tolerogenic APCs and suppressor T cells. Inter-
estingly, IL-10 is dispensable for murine pregnancy in the germ
free environment, but crucial when LPS is present (57), suggesting
that IL-10 is important for controlling inflammation at the fetal–
maternal interface. This is not dissimilar to the gut where bacteria
colonized, but not germ free mice, with IL-10 deficiency develop
severe enterocolitis (123, 124), and humans with defects in IL-10
signaling pathway develop early onset inflammatory bowel disease
(125, 126). In the gut, it has been shown that it is the pathogenic T
cells that cause disease in the IL-10-deficient mice (81). Further-
more, recent evidence suggests that IL-10 may enhance Treg cell
function and augment suppression of pathogenic Th17 cells (127,
128). It remains to be seen whether IL-10 plays similar roles in
pregnancy. Nevertheless, it is clear that IL-10 is a crucial regula-
tory cytokine at mucosal surfaces in the presence of inflammation
and foreign antigens. Indeed pre-eclampsia, rather than being an
overt rejection of the fetus, is more like a pro-inflammatory state
with flaws in the regulatory mechanisms, including reduced IL-
10, altered decidual DC-SIGN+ APCs, and impaired suppressor T
cell (iTreg cells and CD4+HLA-G+ T cells) differentiation; further
fueled by enhanced pro-inflammatory effectors such as raised IL-6
level and enhanced Th17 cell differentiation.
CONCLUDING REMARKS
The fetal–maternal interface is an important frontier for immunol-
ogy, as it represents the junctional point between two immunolog-
ically distinct individuals. Within this mucosal surface, the various
maternal innate and adaptive immune cells must work together to
ensure tolerance toward invading fetal cells and foreign fetal anti-
gens. Whilst several APCs are present in the decidua, CD14+DC-
SIGN+ APCs are unique at this interface and play central roles
in regulating T cell responses, by inducing Foxp3+ iTreg cells and
CD4+HLA-G+ suppressor T cells. Some evidence suggests that
IL-10 may be an important factor in these processes. Certainly
in pre-eclampsia, where there is relative deficiency of IL-10, these
tolerance mechanisms are impaired. Whether CD14+DC-SIGN+
APCs also influence decidual Th17 cell differentiation remains
unknown and requires further investigations.
On the other hand, decidual NK cells, on top of their role in
modulating trophoblast invasion and vascular remodeling,are able
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FIGURE 3 | Summary of proposed innate and adaptive interactions in
human pregnancy. Decidual DC-SIGN+ APCs appear to be a central player in
these interactions. dNK cells interact with DC-SIGN+ APCs via ICAM3, this
leads to release of IFNγ, which in turn upregulates IDO in DC-SIGN+ APCs, as
well as inhibiting Th17 cell differentiation. The tolerogenic DC-SIGN+ APCs
function to induce iTreg cells from naïve CD4+ T cells (Th0), Treg cells in turn
regulated DC-SIGN+ APCs via CTLA-4 and B7 (CD80 and CD86) interaction,
further increasing IDO expression. IL-10 from dNK cells and DC-SIGN− dMacs
acts to upregulate HLA-G expression by DC-SIGN+ APCs; the HLA-G is then
passed onto activated T cells via trogocytosis, resulting in accumulation of
CD4+HLA-G+ T suppressor cells. In pre-eclampsia, several check points are
affected as marked by the “No symbol.” These include reduced IL-10 level,
reduced HLA-G expression by DC-SIGN+ APCs, reduced generation of
CD4+HLA-G+ T suppressor cells, and reduced iTreg cell induction. Other yet
unknown mechanisms may also be affected in pre-eclampsia marked by the
red question mark, including IFNγ production by dNKs, CTLA-4 expression by
Treg cells and interaction with B7 molecules, as well as IDO expression and
TGFβ production by DC-SIGN+ APCs.
to regulate decidual Th17 differentiation by their production of
IFNγ. Interestingly, their production of IFNγ also modulate decid-
ual CD14+DC-SIGN+ APCs by upregulating their IDO expres-
sion to enhance Treg cell expansion. Whether these processes are
affected in pre-eclampsia remain to be seen. These interactions are
summarized in Figure 3. Clearly, there are likely many other innate
and adaptive interactions involving different cell types,which work
to foster the delicate balance of immune tolerance at the fetal–
maternal interface. Disturbance of the quality and quantity of
these interactions likely contribute to the pathogenesis of pre-
eclampsia, which like so many diseases of the modern era, is a
disease of immune dysregulation.
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